A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Exclusion Criteria

• •Disease-Specific Exclusions:
• •Radiotherapy for RCC within 14 days prior to treatment
• •Active central nervous system disease
• •Uncontrolled pleural effusion, pericardial effusion, or ascites
• •Uncontrolled hypercalcemia
• •Any other malignancies within 5 years except for low-risk prostate cancer or those with negligible risk of metastasis or death
• •General Medical Exclusions:
• •Life expectancy less than 12 weeks
• •Participation in another experimental drug study within 4 weeks prior to treatment
• •Pregnant or lactating women
• •Known hypersensitivity to any component of atezolizumab or other study medication
• •History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes mellitus
• •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis
• •Positive human immunodeficiency virus test
• •Active or chronic hepatitis B or C
• •Severe infections within 4 weeks prior to treatment
• •Exposure to oral or IV antibiotics within 2 weeks prior to treatment
• •Live attenuated vaccines within 4 weeks prior to treatment (for influenza vaccination participants must agree not to receive live, attenuated influenza vaccine within 4 weeks prior to treatment, during treatment or within 5 months following the last dose)
• •Significant cardiovascular disease
• •Prior allogeneic stem cell or solid organ transplantation
• •Prior treatment with cluster of differentiation 137 agonists, anti-cytotoxic T-lymphocyte associated protein-4, anti-programmed death (PD)-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
• •Treatment with immunostimulatory agents for non-malignant conditions within 6 weeks or immunosuppressive agents within 2 weeks prior to treatment
• •Bevacizumab- and Sunitinib-Specific Exclusions:
• •History of hypertensive crisis or hypertensive encephalopathy
• •Baseline electrocardiogram showing corrected QT interval greater than 460 milliseconds